Breaking News
CELZ has been granted a very broad patent on the TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS on people who are at risk or have heart failure.
Breaking News
CELZ has been granted a very broad patent on the TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS on people who are at risk or have heart failure.
Breaking News
CELZ has been granted a very broad patent on the TREATMENT OF HEART FAILURE AND/OR POST INFARCT PATHOLOGICAL REMODELING BY EX VIVO REPROGRAMMED IMMUNE CELLS on people who are at risk or have heart failure.

A Regenerative Medicine and Immunotherapy Company

Advancing Our Disruptive Technology Platforms

Type 1 Diabetes Clinical TrialLower Back Pain Clinical Trial

Programs

Airing on CNBC and Fox Business throughout October

Who we are

Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company committed to improving patient lives via a regenerative approach to immunology, endocrinology, urogynecology, and orthopedics.

Our company is supported by a leadership team with extensive experience, a novel scientifically based patent portfolio and a well defined business strategy.

Innovations

Creative Medical Technology Holdings, Inc. is advancing multiple unique platforms—supercharged autologous therapy, enhanced allogenic cell platform, reprogrammed
cells, and rapid autologous therapies.

Read More

Creative Medical
Technology Difference

Our company offers new solutions to medical conditions with its innovative regenerative medicine and immunotherapy technologies.

Oustanding Team

The company benefits from an experienced management team as well as a base of talented scientific & medical consultants with vast industry experience.

1

Disruptive Technologies

Our innovative technologies are disruptive in the field of regenerative medicine and immunotherapy.

2

Robust Pipeline

Creative Medical Technology Holdings, Inc. continues to develop a robust development pipeline.

3

Sizable Markets

Our Innovative regenerative medical technology can treat various conditions, leading to sizable markets.

4

Intellectual Property

Creative Medical Technology Holdings, Inc. has developed a robust intellectual property portfolio with technologies to improve patient lives in the areas of immunology, endocrinology, urogynecology, and orthopedics. The company currently has over 60 pending or issued patents.

Research
Collaborations

We work with Not For Profit and For Profit Organizations in the further development of our technologies. As related to Translational Projects we have defined policies and protocols in place that allows for indirect costs up to 25 percent of the direct costs. Direct costs + 25% of direct costs = Total project budget.

Learn More

Current or Latest news about Creative Medical Technology Holdings

Read about our latest stories in the press.

Connect With Us

Interested in learning more?
Connect with us now by filling out our form on our contact page.

Contact Us Now

Innovations

ImmCelz® is our first autologous immunotherapy platform that utilizes secreted factors from universal donor cells to supercharge the patient's own immune cells. Our enhanced allogenic cell platform, AlloStemTM, utilizes an unique perinatal derived tissue cell to treat a variety of indications. iPSCELZTM, our cellular reprogramming platform, is a developing platform with the potential ability to differentiate any cell type in the body from any patient. The StemSpine®, OvaStem®, and CaverStem® programs utilize our rapid autologous therapy platform.